2-(1-氨基丙基)苯胺 | 133332-53-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(1-氨基丙基)苯胺
• 英文名称: 2-(1-Aminopropyl)aniline
• CAS: 133332-53-3
• 化学式: C₉H₁₄N₂
• 分子量: 150.22
• InChiKey: UUZCNFWPRJSBHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'HORMONE DE LIBÉRATION DES GONADOTROPHINES, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：SK CHEMICALS CO LTD

  公开号：WO2013129879A1

  公开（公告）日：2013-09-06

  The present invention provides gonadotropin releasing hormone receptor antagonists and the pharmaceutical composition comprising the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

  本发明提供了促性腺激素释放激素受体拮抗剂及包括其的药物组合物，可用于预防或治疗与性激素相关的疾病，如子宫内膜异位症、闭经、月经不调、子宫肌瘤、子宫肌瘤、多囊卵巢综合征、红斑狼疮、多毛症、性早熟、身材矮小、痤疮、脱发、性腺类固醇依赖性肿瘤、促性腺激素产生性垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕症，以及阿尔茨海默病。
• GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：SK CHEMICALS CO., LTD.

  公开号：US20150166558A1

  公开（公告）日：2015-06-18

  Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

  揭示了一种促性腺激素释放激素受体拮抗剂和包括该拮抗剂的药物组合物，可用于预防或治疗与性激素相关的疾病，如子宫内膜异位症、闭经、月经不调、子宫肌瘤、子宫纤维瘤、多囊卵巢综合征、红斑狼疮、多毛症、性早熟、身材矮小、痤疮、脱发、性腺类固醇依赖性肿瘤、促性腺激素产生垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕症，以及阿尔茨海默病。
• COMPOSITIONS AND METHODS FOR GENERATING WHITE LIGHT
  申请人：Li Jing

  公开号：US20110049560A1

  公开（公告）日：2011-03-03

  Crystalline inorganic-organic hybrid structures having a plurality of layers of a repeating unit characterized by a first organic ligand layer, a second organic ligand layer, and a two-dimensional semiconducting inorganic double layer having two opposing surfaces therebetween, wherein the two-dimentional semiconducting inorganic double layer is characterized by two single atom thick layers of a II-chalcogenide compound; and the first organic ligand layer and the second organic ligand layer are attached to the two opposing surfaces of the two-dimensional semiconducting inorganic double layer through a covalent bond or a coordinate covalent bond between the compounds of the organic ligand layers and the metal cation species of the II-VI chalcogenide compounds, so that the semiconducting inorganic double layer is directed by the compounds of the two opposing organic layers to form ordered crystal lattices. Methods for the preparation of the hybrid structures are also disclosed.

  具有多个重复单元层的晶态无机-有机杂化结构，其特征在于第一有机配体层、第二有机配体层和具有两个相对表面之间的二维半导体无机双层，其中二维半导体无机双层特征为II族硫属化合物的两个单原子厚度层；第一有机配体层和第二有机配体层通过有机配体层的化合物和II-VI族硫属化合物的金属阳离子种类之间的共价键或配位共价键连接到二维半导体无机双层的两个相对表面上，以便由两个相对有机层的化合物指导半导体无机双层形成有序晶体格子。还公开了制备杂化结构的方法。
• Aryl and heteroaryl fused aminoalkyl-imidazole derivatives
  申请人：Neurogen Corporation

  公开号：US20020082425A1

  公开（公告）日：2002-06-27

  Disclosed are compounds of the formula: 1 or the pharmaceutically acceptable non-toxic salts thereof wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, and D are variables defined herein. Such compounds useful in treatment of obesity and diabetes. The invention also provides labeled probes for the localization of cellular receptors that are involved in the modulation of blood glucose levels.

  本发明揭示了以下公式的化合物：1或其药学上可接受的非毒性盐，其中X，R1，R2，R3，R4，R5，R6，R7，A，B，C和D是在此定义的变量。这些化合物在肥胖和糖尿病的治疗中有用。本发明还提供了用于定位参与调节血糖水平的细胞受体的标记探针。
• Alicyclic diamines, alicyclic diisocyanates and polyisocyanato-isocyanurates and method for the preparation thereof
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0394058A1

  公开（公告）日：1990-10-24

  Herein disclosed are an α-(aminocydonexyl)alkylamine represented by the following general formula (II): wherein R represents hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms, provided that the amino group bonded to the cyclohexyl group may be in either of the 2-, 3- and 4-positions and a method for preparing it; an a-(isocyanatocyclohexyl)alkylisocyanate of Formula (II) wherein the amino groups are replaced with isocyanato groups and a method for preparing it; polyisocyanato-isocyanurate represented by the following general formula (IV): wherein Ri, R2 and R3 may be the same or different and each represents a group represented by the following general formula: wherein R represents hydrogen atom or an alkyl group having 1 to 5 carbon atoms and n is an integer ranging from 1 to 5 and a method for preparing it; and a resin obtained by polymerizing an organic polyisocyanate containing not lower than 10% by weight of the polyisocyanato-isocyanurate represented by Formula (IV) and a compound having at least two active hydrogen atoms as well as a resin composition for coating materials which comprises the resin.

  本发明公开了由以下通式(II)代表的α-(氨基环己基)烷基胺： 其中 R 代表氢原子或具有 1 至 5 个碳原子的低级烷基，但与环己基键合的氨基可位于 2、3 和 4 位中的任一位置；式（II）的 a-(异氰基环己基)烷基异氰酸酯（其中氨基被异氰酸基取代）及其制备方法；由以下通式（IV）表示的聚异氰酸酯： 其中 Ri、R2 和 R3 可以相同或不同，且各自代表下式通式所代表的基团： 其中 R 代表氢原子或具有 1 至 5 个碳原子的烷基，n 为 1 至 5 的整数，以及制备方法；通过聚合有机多异氰酸酯获得的树脂，该有机多异氰酸酯含有不低于 10%（按重量计）的由式(IV)代表的多异氰酸酯和至少具有两个活泼氢原子的化合物，以及包含该树脂的用于涂层材料的树脂组合物。